FDA To Centocor: Show Me The REMS For Ustekinumab
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After an earlier three-month delay of its ustekinumab user fee date, Centocor is facing yet another setback in getting FDA approval for the potentially first-in-class monoclonal antibody to treat chronic moderate to severe plaque psoriasis in adults
You may also be interested in...
Sidebar: Biologics In The Spotlight: J&J’s Ustekinumab & Golimumab
Both J&J-sponsored MAbs on the 2009 calendar, ustekinumab and Simponi (golimumab), are looking to break into established biologic markets (psoriasis, rheumatoid arthritis) with products that have a significant dosing advantage over approved biologics.
FDA Panel Recommends Centocor’s Ustekinumab Approval; Questions Dosing
Centocor should conduct additional studies of ustekinumab to evaluate potential interim doses, according to FDA's Dermatologic and Ophthalmic Drugs Advisory Committee
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee